{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:57:57Z","timestamp":1795132677378,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-07793-9","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:30:23Z","timestamp":1774513823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing demographic and clinical characteristics and healthcare resource utilization of patients with schizophrenia with inadequate response to antipsychotic treatment"],"prefix":"10.1186","volume":"26","author":[{"given":"Andre","family":"Hejazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Bron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mercedes","family":"Perez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Victoria","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Biskupiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"7793_CR1","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed., text rev.). 2022. https:\/\/doi.org\/10.1176\/appi.books.9780890425787.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"7793_CR2","unstructured":"National Institute of Mental Health. Schizophrenia [Internet]. 2022 May 12. Available from: https:\/\/www.nimh.nih.gov\/health\/statistics\/schizophrenia."},{"issue":"12","key":"7793_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172\u201381. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.1737.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"7793_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jphs.12027","volume":"4","author":"PR Desai","year":"2013","unstructured":"Desai PR, Lawson KA, Barner JC, Rascati KL. Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. J Pharm Health Serv Res. 2013;4(4):187\u201394. https:\/\/doi.org\/10.1111\/jphs.12027.","journal-title":"J Pharm Health Serv Res"},{"key":"7793_CR5","doi-asserted-by":"crossref","unstructured":"Kadakia A, Catillon M, Fan Q, et al. The economic burden of schizophrenia in the United States in 2019. J Clin Psychiatry. 2022.","DOI":"10.4088\/JCP.22m14458"},{"key":"7793_CR6","volume-title":"Use and health","author":"Substance Abuse and Mental Health Services Administration","year":"2022","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the united states: results from the 2021 National survey on drug PEP22-07-01-005. Use and health. NSDUH Series H-57. Substance Abuse and Mental Health Services Administration: HHS Publication No. Center for Behavioral Health Statistics and Quality; 2022. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report."},{"issue":"5","key":"7793_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318\u201378. https:\/\/doi.org\/10.3109\/15622975.2012.696143.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"7793_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and secondgeneration antipsychotics in comparative randomized controlled trials: A meta-analysis. World Psychiatry. 2018;17(3):330\u201340. https:\/\/doi.org\/10.1002\/wps.20579.","journal-title":"World Psychiatry"},{"issue":"2","key":"7793_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M De Hert","year":"2012","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114\u201326. https:\/\/doi.org\/10.1038\/nrendo.2011.156.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"7793_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","volume":"360","author":"WA Ray","year":"2009","unstructured":"Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225\u201335. https:\/\/doi.org\/10.1056\/NEJMoa0806994.","journal-title":"N Engl J Med"},{"key":"7793_CR11","unstructured":"Uhlyar S, Rey JA, Valbenazine (Ingrezza), editors. The first FDA-approved treatment for tardive dyskinesia. P T. 2018;43(6):328\u201331. PubMed PMID: 29896031."},{"issue":"6","key":"7793_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1192\/bjp.bp.117.201475","volume":"211","author":"J Lally","year":"2017","unstructured":"Lally J, Ajnakina O, Stubbs B, Cullinane M, Murphy KC, Gaughran F, et al. Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of longterm outcome studies. Br J Psychiatry. 2017;211(6):350\u20138. https:\/\/doi.org\/10.1192\/bjp.bp.117.201475.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"7793_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","volume":"29","author":"JL Kennedy","year":"2014","unstructured":"Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: A systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63\u201376. https:\/\/doi.org\/10.1097\/YIC.0b013e32836508e6.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"7793_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40263-02200932-2","volume":"36","author":"CU Correll","year":"2022","unstructured":"Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Sepp\u00e4l\u00e4 N, et al. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs. 2022;36(7):659\u201379. https:\/\/doi.org\/10.1007\/s40263-02200932-2.","journal-title":"CNS Drugs"},{"key":"7793_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","volume":"9","author":"A Semahegn","year":"2020","unstructured":"Semahegn A, Torpey K, Manu A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9:17. https:\/\/doi.org\/10.1186\/s13643-020-1274-3.","journal-title":"Syst Rev"},{"issue":"3","key":"7793_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/JCP.0000000000001388","volume":"41","author":"TM Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es TM, Guimar\u00e3es MRC, Oliveira \u00cdAF, Leoni RF, Santos AC, Dursun SM, et al. Mononitrate isosorbide as an adjunctive therapy in schizophrenia: A randomized controlled crossover trial. J Clin Psychopharmacol. 2021;41(3):260\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000001388.","journal-title":"J Clin Psychopharmacol"},{"key":"7793_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.psychres.2018.02.018","volume":"262","author":"H Shen","year":"2018","unstructured":"Shen H, Li R, Yan R, Zhou X, Feng X, Zhao M, et al. Adjunctive therapy with Statins in schizophrenia patients: A meta-analysis and implications. Psychiatry Res. 2018;262:84\u201393. https:\/\/doi.org\/10.1016\/j.psychres.2018.02.018.","journal-title":"Psychiatry Res"},{"issue":"S1","key":"7793_CR18","doi-asserted-by":"publisher","first-page":"S799","DOI":"10.1016\/j.eurpsy.2017.01.1541","volume":"41","author":"H Ahlem","year":"2017","unstructured":"Ahlem H, Zgueb Y, Ouali U, Laajili Y, Alaya SB, Jomli R, et al. Family burden in caregivers of schizophrenia patients. Eur Psychiatry. 2017;41(S1):S799\u2013800. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.01.1541.","journal-title":"Eur Psychiatry"},{"key":"7793_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S96649","volume":"12","author":"HY Chong","year":"2016","unstructured":"Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: A systematic review. Neuropsychiatr Dis Treat. 2016;12:357\u201373. https:\/\/doi.org\/10.2147\/NDT.S96649.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"7793_CR20","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4088\/JCP.15m10278","volume":"77","author":"M Cloutier","year":"2016","unstructured":"Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, et al. The economic burden of schizophrenia in the united States in 2013. J Clin Psychiatry. 2016;77(6):764\u201371. https:\/\/doi.org\/10.4088\/JCP.15m10278.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"7793_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1034\/j.1600-0447.2002.02209","volume":"105","author":"D Folsom","year":"2002","unstructured":"Folsom D, Jeste DV. Schizophrenia in homeless persons: A systematic review of the literature. Acta Psychiatr Scand. 2002;105(6):404\u201313. https:\/\/doi.org\/10.1034\/j.1600-0447.2002.02209.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"7793_CR22","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/eip.13113","volume":"15","author":"AG Szmulewicz","year":"2021","unstructured":"Szmulewicz AG, Benson NM, Hsu J, Hern\u00e1n MA, \u00d6ng\u00fcr D. Effects of COVID-19 pandemic on mental health outcomes in a cohort of early psychosis patients. Early Interv Psychiatry. 2021;15(6):1799\u2013802. https:\/\/doi.org\/10.1111\/eip.13113.","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"7793_CR23","doi-asserted-by":"publisher","first-page":"Article2361","DOI":"10.1186\/s12888-019-2361-7","volume":"19","author":"S Fazel","year":"2019","unstructured":"Fazel S, Geddes JR, Kushel M. The prevalence of schizophrenia and other psychotic disorders among homeless people: A systematic review and meta-analysis. BMC Psychiatry. 2019;19(1):Article2361. https:\/\/doi.org\/10.1186\/s12888-019-2361-7.","journal-title":"BMC Psychiatry"},{"key":"7793_CR24","doi-asserted-by":"publisher","unstructured":"Chwastiak LA, Rosenheck RA. Unemployment, homelessness, and other societal outcomes in patients with treatment-resistant schizophrenia: A retrospective cohort study. BMC Psychiatry. 2022;22(1):Article4022. https:\/\/doi.org\/10.1186\/s12888-022-04022-x.","DOI":"10.1186\/s12888-022-04022-x"},{"issue":"5 Suppl","key":"7793_CR25","first-page":"S87","volume":"25","author":"CU Correll","year":"2019","unstructured":"Correll CU, Howes OD, Schizophrenia. Opportunities to improve outcomes and reduce economic burden through managed care. Am J Manag Care. 2019;25(5 Suppl):S87\u201395. https:\/\/www.ajmc.com\/view\/schizophrenia-opportunities-to-improve-outcomes-and-reduceeconomic-burden-through-managed-care.","journal-title":"Am J Manag Care"},{"issue":"11","key":"7793_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/070674371506001102","volume":"60","author":"T Aubry","year":"2015","unstructured":"Aubry T, Nelson G, Tsemberis S. Housing first for people with severe mental illness who are homeless: A review of the research and findings from the at Home\/Chez Soi demonstration project. Can J Psychiatry. 2015;60(11):467\u201374. https:\/\/doi.org\/10.1177\/070674371506001102.","journal-title":"Can J Psychiatry"},{"key":"7793_CR27","doi-asserted-by":"publisher","first-page":"Article1339801","DOI":"10.3389\/fpsyt.2023.1339801","volume":"14","author":"R Hird","year":"2024","unstructured":"Hird R, Radhakrishnan R, Tsai J. A systematic review of approaches to improve medication adherence in homeless adults with psychiatric disorders. Front Psychiatry. 2024;14:Article1339801. https:\/\/doi.org\/10.3389\/fpsyt.2023.1339801.","journal-title":"Front Psychiatry"},{"issue":"7","key":"7793_CR28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Tanskanen A, Taipale H, Meht\u00e4l\u00e4 J, Vattulainen P, Correll CU. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686\u201393. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1322.","journal-title":"JAMA Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-07793-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:18:07Z","timestamp":1777943887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-07793-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7793"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-07793-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7158569\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Utah Institutional Review Board approved this study. Informed consent was waived due to the retrospective design, which utilized de-identified EHR data. Human Ethics and Consent to Participate declarations: not applicable. IRB number: 00159998.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author M. Mercedes Perez-Rodriguez is a consultant of Neurocrine and Mitsubishi Tanabe Pharma Corporation, and has received grant funding from Neurocrine.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"367"}}